Foghorn Therapeutics Inc. (FHTX) Operating cash flow 2019–2025
Foghorn Therapeutics Inc. (FHTX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$86.1MFY2025 · since FY2019: -$46.3M → -$86.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$86.1M | +14.2% |
| FY2024 | -$100.4M | +15.0% |
| FY2023 | -$118.1M | -161.0% |
| FY2022 | $193.6M | +485.3% |
| FY2021 | -$50.3M | -60.6% |
| FY2020 | -$31.3M | +32.5% |
| FY2019 | -$46.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More FHTX financial trends
FHTX RevenueFHTX Net incomeFHTX Net marginFHTX Gross profitFHTX Gross marginFHTX Operating incomeFHTX Operating marginFHTX Free cash flowFHTX Capital expendituresFHTX Return on equityFHTX Stock buybacksFHTX Dividends paidFHTX Total assetsFHTX Total liabilitiesFHTX Shareholders’ equityFHTX overview →